Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model

Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling

(2016) Rajbharan Yadav et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutablePseudomonas aeruginosa

(2016) Vanessa E. Rees et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect of different renal function on antibacterial effects of piperacillin againstPseudomonas aeruginosaevaluated via the hollow-fibre infection model and mechanism-based modelling

(2016) Phillip J. Bergen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii : pharmacodynamics of new dosing strategies

(2016) Gauri G. Rao et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cystic fibrosis lung environment and Pseudomonas aeruginosa infection

(2016) Anjali Y. Bhagirath et al.   BMC Pulmonary Medicine

Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii

(2015) Rajbharan Yadav et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling

(2015) Jürgen B. Bulitta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort

(2015) Mohd H. Abdul-Aziz et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs

(2015) Alexis Tabah et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cystic Fibrosis Lung Infections: Polymicrobial, Complex, and Hard to Treat

(2015) Laura M. Filkins et al.   PLoS Pathogens

Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design

(2013) Cornelia B. Landersdorfer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis

(2013) Stefanie Hennig et al.   CLINICAL PHARMACOKINETICS

Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective

(2012) Anders Folkesson et al.   NATURE REVIEWS MICROBIOLOGY

Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models

(2011) Jurgen B. Bulitta et al.   AAPS Journal

Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT

(2011) Jurgen Bernd Bulitta et al.   AAPS Journal

Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases

(2011) Arnold Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibiotic treatment of CF lung disease: From bench to bedside

(2011) Robert Bals et al.   Journal of Cystic Fibrosis

Bacterial hypermutation: clinical implications

(2011) A. Jolivet-Gougeon et al.   JOURNAL OF MEDICAL MICROBIOLOGY

A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients

(2011) Jeffery T. Zobell et al.   PEDIATRIC PULMONOLOGY

Pseudomonas Aeruginosa: Resistance to the Max

(2011) Keith Poole   Frontiers in Microbiology

The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression

(2010) A. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy

(2010) Antonio Oliver   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

Suboptimal Ciprofloxacin Dosing as a Potential Cause of DecreasedPseudomonas aeruginosaSusceptibility in Children with Cystic Fibrosis

(2010) Emmanuelle Guillot et al.   PHARMACOTHERAPY

Cystic Fibrosis Pulmonary Guidelines

(2009) Patrick A. Flume et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution

(2009) Jason A. Roberts et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis

(2009) Daniel J. Van Meter et al.   PEDIATRIC PULMONOLOGY

Effect of mutatorP. aeruginosaon antibiotic resistance acquisition and respiratory function in cystic fibrosis

(2009) Agnes Ferroni et al.   PEDIATRIC PULMONOLOGY

Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa

(2008) J. B. Bulitta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genetic Adaptation of Pseudomonas aeruginosa to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation

(2008) A. Mena et al.   JOURNAL OF BACTERIOLOGY

Association between Hypermutator Phenotype, Clinical Variables, Mucoid Phenotype, and Antimicrobial Resistance in Pseudomonas aeruginosa

(2008) D. J. Waine et al.   JOURNAL OF CLINICAL MICROBIOLOGY